文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

新加坡成人接种2剂mRNA或灭活新冠疫苗联合或不联合加强针对COVID-19发病率和严重程度的影响分析

Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
PubMed 文献 · JAMA Netw Open · 2022-08-01
一句话结论新加坡队列显示mRNA加强针对重症COVID-19的保护15–60天为87.4%、5–6个月为87.2%,3剂灭活疫苗为69.6%。

这项针对新加坡2 441 581名30岁及以上居民的队列研究,评估了Omicron流行期间不同疫苗加强组合对确诊感染和重症COVID-19的保护效果。mRNA加强针对确诊感染的保护在15–60天为31.7%–41.3%,5个月及以上降至-2.8%–14.6%。对重症COVID-19,mRNA加强针在15–60天为87.4%,5–6个月为87.2%,不同组合间无显著差异;3剂灭活疫苗对重症的保护为69.6%。作者认为mRNA加强针对重症的保护在6个月内持久,3剂灭活疫苗保护强于2剂但弱于3剂mRNA。

要点

  • mRNA加强针对重症COVID-19的保护:15–60天87.4%(95%CI 83.3%-90.5%),5–6个月87.2%(95%CI 84.2%-89.7%),不同疫苗组合间无显著差异。
  • 3剂灭活COVID-19疫苗对重症的保护为69.6%(95%CI 48.7%-81.9%),弱于3剂mRNA。
  • mRNA加强针对确诊感染的保护在15–60天为31.7%–41.3%,5个月及以上降至-2.8%–14.6%。
  • 研究纳入2 441 581人,其中60岁及以上846 110人(34.7%),确认感染319 943例(13.1%),重症1 513例(0.4%)。

适用人群与场景

  • 新加坡30岁及以上居民,截至2022年3月10日已接种至少2剂mRNA COVID-19疫苗(Pfizer-BioNTech BNT162b2或Moderna mRNA-1273)或灭活SARS-CoV-2疫苗(Sinovac CoronaVac或Sinopharm BBIBP-CorV)。
  • 排除2021年12月27日前已知SARS-CoV-2感染、第二剂疫苗当日或之前感染、再感染病例。

研究设计与关键结果

  • 研究类型为队列研究,纳入2 441 581名符合条件个体(1 279 047名女性[52.4%],846 110名60岁及以上[34.7%]),2021年12月27日至2022年3月10日报告319 943例(13.1%)确诊SARS-CoV-2感染,其中1 513例(0.4%)为重症COVID-19。
  • 暴露为2或3剂Pfizer-BioNTech BNT162b2、Moderna mRNA-1273、Sinovac CoronaVac或Sinopharm BBIBP-CorV。
  • mRNA加强针在加强后15–60天对确诊感染的估计有效性为31.7%–41.3%(4种加强组合:同源BNT162b2、同源mRNA-1273、2剂BNT162b2/mRNA-1273加强、2剂mRNA-1273/BNT162b2加强)。
  • 加强后5个月及以上,mRNA加强针对确诊感染的估计有效性下降,范围为-2.8%至14.6%。
  • mRNA加强针对重症COVID-19的估计有效性:加强后15–60天为87.4%(95%CI 83.3%-90.5%),加强后5–6个月为87.2%(95%CI 84.2%-89.7%),不同疫苗组合间无显著差异。
  • 3剂灭活COVID-19疫苗接种后15天至330天,无论组合,对重症COVID-19的加强有效性估计为69.6%(95%CI 48.7%-81.9%)。

证据类型、等级与局限

  • 证据类型:队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为mRNA加强针对重症COVID-19的保护在6个月内持久。
  • 作者认为3剂灭活SARS-CoV-2疫苗接种提供比2剂更强的保护,但与3剂mRNA相比保护较弱。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Assessing booster effectiveness of COVID-19 mRNA vaccine and inactivated SARS-CoV-2 vaccine over longer time intervals and in response to any further SARS-CoV-2 variants is crucial in determining optimal COVID-19 vaccination strategies.

OBJECTIVE: To determine levels of protection against severe COVID-19 and confirmed SARS-CoV-2 infection by types and combinations of vaccine boosters in Singapore during the Omicron wave.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study included Singapore residents aged 30 years or more vaccinated with either at least 2 doses of mRNA COVID-19 vaccines (ie, Pfizer-BioNTech BNT162b2 or Moderna mRNA-1273) or inactivated SARS-CoV-2 vaccines (Sinovac CoronaVac or Sinopharm BBIBP-CorV) as of March 10, 2022. Individuals with a known SARS-CoV-2 infection prior to December 27, 2021, an infection on or before the date of their second vaccine dose, or with reinfection cases were excluded.

EXPOSURES: Two or 3 doses of Pfizer-BioNTech BNT162b2, Moderna mRNA-1273, Sinovac CoronaVac, or Sinopharm BBIBP-CorV.

MAIN OUTCOMES AND MEASURES: Notified infections from December 27, 2021, to March 10, 2022, adjusted for age, sex, race, housing status, and calendar days. Estimated booster effectiveness, defined as the relative incidence-rate reduction of severe disease (supplemental oxygen, intensive care, or death) or confirmed infection following 3-dose vaccination compared with 5 months after second mRNA dose, was determined using binomial regression.

RESULTS: Among 2 441 581 eligible individuals (1 279 047 [52.4%] women, 846 110 (34.7%) aged 60 years and older), there were 319 943 (13.1%) confirmed SARS-CoV-2 infections, of which 1513 (0.4%) were severe COVID-19 cases. mRNA booster effectiveness against confirmed infection 15 to 60 days after boosting was estimated to range from 31.7% to 41.3% for the 4 boosting combinations (homologous BNT162b2, homologous mRNA-1273, 2-dose BNT162b2/mRNA-1273 booster, and 2-dose mRNA-1273/BNT162b2 booster). Five months and more after boosting, estimated booster effectiveness against confirmed infection waned, ranging from -2.8% to 14.6%. Against severe COVID-19, estimated mRNA booster effectiveness was 87.4% (95% CI, 83.3%-90.5%) 15 to 60 days after boosting and 87.2% (95% CI, 84.2%-89.7%) 5 to 6 months after boosting, with no significant difference comparing vaccine combinations. Booster effectiveness against severe COVID-19 15 days to 330 days after 3-dose inactivated COVID-19 vaccination, regardless of combination, was estimated to be 69.6% (95% CI, 48.7%-81.9%).

CONCLUSIONS AND RELEVANCE: Booster mRNA vaccine protection against severe COVID-19 was estimated to be durable over 6 months. Three-dose inactivated SARS-CoV-2 vaccination provided greater protection than 2-dose but weaker protection compared with 3-dose mRNA.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Ng OT, Marimuthu K, Lim N, et al. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore. JAMA Netw Open. 2022. PMID: 36018588. doi:10.1001/jamanetworkopen.2022.28900

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。